ARTICLE | Clinical News
Baricitinib: Additional Phase III data
July 20, 2015 7:00 AM UTC
Additional data from the double-blind, international Phase III RA-BUILD trial in 684 patients with moderately to severely active RA who had an inadequate response to, or were intolerant of, >=1 conven...